Gereguleerd
- Risiconiveau
- Hoog
- Risico-rendement
- Zeer slecht
- Starten vanaf
- €250
De financiering is gesloten. De pagina blijft online ter informatie; vergelijkbare open projecten staan hieronder.
Biogener
Italië
Biogenera is a Bologna biotech that has spent 17 years developing a new type of cancer drug that switches off a gene (MYCN) which drives some of the most aggressive childhood tumours; it wants to prove the drug in a first human trial and then license it to a large pharmaceutical company.
Kerncijfers
- Verwacht rendement
- 5–7×
- schatting van het platform
- Waardering
- €89,952,077
- Aangeboden belang
- 0,3%
- Starten vanaf
- €576
- Doelbedrag
- €249,984
Wat u bezit, hoe het kan opbrengen, en wanneer
Wat bezit ik?
0,3% van het bedrijf
Kijk in de documenten hoe de aandelen worden gehouden en welke rechten ze geven.
Hoe kan het opbrengen?
Het platform schat 5–7×
Meestal alleen als het bedrijf wordt verkocht of naar de beurs gaat. Schattingen zijn beweringen van het platform zelf.
Kapitaal loopt risico. De meeste start-ups mislukken; schattingen zijn beweringen van het platform zelf. Aandelen zijn moeilijk te verkopen vóór een exit.
Zou de AI investeren?
AI 58 GemiddeldOnze AI geeft dit project 58 van de 100: Gemiddeld. Zo werkt de AI-score
Informatie, geen persoonlijk beleggingsadvies. De AI-score beoordeelt de documenten die het platform publiceert, kan onjuist zijn en voorspelt geen rendement.
AI-analyse
AIBiogenera S.p.A. — Crowdfunding Investor Memo
Biogenera is a Bologna biotech that has spent 17 years developing a new type of cancer drug that switches off a gene (MYCN) which drives some of the most aggressive childhood tumours; it wants to prove the drug in a first human trial and then license it to a large pharmaceutical company.
Sector: Biotech — paediatric oncology, orphan drugs · Stage: Pre-revenue, entering first human trial (Phase I planned Q1 2027) · HQ: Bologna area (Alto Reno Terme / Ozzano dell'Emilia), Italy · Raise: €250K minimum – €5.0M maximum on CrowdFundMe; €469K raised at 26 Aug 2026
Snapshot
|
1 · Is the price fair? 💶 |
3 / 5 — Stretched but arguable. The €90m pre-money sits above the 2025 average for VC-priced biotech Series A rounds (≈ $79M, Qubit Capital) and below the $150–300M range recorded for Phase 1–2 biotechs (Baybridge Bio) — but those are institutional rounds with stronger investor rights, and Biogenera's price has been set by the company itself across successive crowd rounds (€70m in 2021, €80m in 2024). |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 58 / 100 — Average The drug is manufactured to clinical standard and its orphan status is independently confirmed; the biggest gap is money — €0.9m of cash at the end of 2025 against a yearly cash decrease of €1.9m, with the first patient still five months away. |
|
3 · If they do, what could it pay? 🎯 |
Target 5–7x over 4–6 years (stage-standard for a company at this level of funding — the company gives no target of its own). If reached, illustratively 1.5x–4x before fees and future dilution. Method: the disclosed post-money of €95m compared with the next-stage valuations the benchmarks record for biotechs entering or in early trials — $79M Series A average (Qubit Capital, 2026) and $150–400M Series B (Baybridge Bio) — treating dollars and euros as roughly equal for this illustration. The 5–7x target itself would need an equity value of roughly €478m–€668m, above the top of the next-stage valuations we could find on record. These figures do not include dilution from future fundraising rounds, which would reduce an early investor's share and actual returns — see the dilution section for how this works. |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We verified against public sources four of the five orphan-drug designations (EMA and FDA register numbers quoted in peer-reviewed papers), the two peer-reviewed studies on the drug, the clinical-research partner (CVBF), the CEO's and CFO's backgrounds, the 2021 and 2024 crowd rounds and the live status of this one. The company's own statutory accounts (2023–2025) give the financial picture; the 2025 accounts are a draft dated 31 March 2026 without an audit opinion in the pack. The 2026–2033 projections, the patent list, the licensing talks, today's cash balance and the fairness opinion behind the €90m price rest on the company's word — see the questions section. Your money is locked in. Crowdfunding shares normally cannot be sold early — expect your money to be tied up for several years, until the company is sold, listed or a similar event happens. |
Three answers, one honest note. The valuation-fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the preconditions in place to reach a stage where an exit or return event can happen: it audits readiness on the disclosed evidence, it is not a probability of success, and even companies with every precondition in place fail more often than they succeed — which is why crowdfunding only works as a small part of a diversified portfolio. The potential-returns range is an illustration of what a successful outcome could pay, drawn from named sector benchmarks, not a forecast. Where something was not in the pack we reviewed, it did not lower any score; it appears in the questions list so you can ask the company directly before investing. The listing was reviewed by CrowdFundMe, a crowdfunding platform licensed under EU Regulation 2020/1503, before going live; where a fact could exist outside the pack (interviews, the company's data room, the platform Q&A) we say so rather than assume the worst. Nothing in this memo is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
De volledige analyse behandelt de lener of het bedrijf, de zekerheid, de kasstroom, de risico's en een oordeel. Log in om deze te lezen.
Informatie, geen persoonlijk beleggingsadvies. De AI-score beoordeelt de documenten die het platform publiceert, kan onjuist zijn en voorspelt geen rendement.
Vraag de AI over dit project
Log in om de AI vragen te stellen over de documenten van dit project.
InloggenSpreekt dit project u aan?
👍 Ja · 0 👎 Nee · 0
Reacties · 0
- Nog geen reacties.
Het platform en vergelijkbare projecten
Aangeboden op
Vergelijkbare open projecten
Kepplair Evolution
Sowefund
- Verwacht rendement
- tot 7×
- schatting van het platform
- Waardering
- €60,000,000
Doel: €9m
Vanaf €500
Bekijk project
Wind Fisher
Sowefund
- Verwacht rendement
- tot 10×
- schatting van het platform
- Waardering
- €9,961,800
Doel: €600k
Vanaf €1,000
Bekijk project
Blumana
Sowefund
- Verwacht rendement
- tot 28×
- schatting van het platform
- Waardering
- €2,799,571
Doel: €750k
Vanaf €1,000
Bekijk project